Profile data is unavailable for this security.
About the company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
- Revenue in USD (TTM)449.00k
- Net income in USD-19.85m
- Incorporated1996
- Employees12.00
- LocationCyclacel Pharmaceuticals Inc200 Connell Dr Ste 1500BERKELEY HEIGHTS 07922-2811United StatesUSA
- Phone+1 (908) 517-7330
- Fax+1 (866) 271-3466
- Websitehttps://cyclacel.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
60 Degrees Pharmaceuticals Inc | 378.20k | -1.07m | 3.55m | 2.00 | -- | -- | -- | 9.37 | -0.1563 | -0.1563 | 0.0564 | 0.6121 | 0.0474 | 0.8827 | 1.90 | 126,066.70 | -9.87 | -- | -- | -- | -23.45 | -- | -208.43 | -- | 6.77 | -- | 0.0217 | -- | -50.40 | -- | 35.51 | -- | -- | -- |
Clearmind Medicine Inc | 0.00 | -8.09m | 3.58m | -- | -- | 0.7104 | -- | -- | -30.92 | -30.92 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -109.55 | -218.20 | -180.61 | -488.96 | -- | -- | -- | -- | -- | -2.90 | 0.0184 | -- | -- | -- | -25.03 | -- | -- | -- |
Atreca Inc | 0.00 | -97.76m | 3.65m | 90.00 | -- | 0.3391 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
Tharimmune Inc | 0.00 | -8.89m | 3.73m | 2.00 | -- | 0.5291 | -- | -- | -111.65 | -111.65 | 0.00 | 8.97 | 0.00 | -- | -- | 0.00 | -130.60 | -- | -173.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
Exicure Inc | 21.77m | 2.97m | 3.84m | 6.00 | 0.2597 | 0.8543 | 0.9912 | 0.1765 | 1.71 | 1.71 | 3.07 | 0.52 | 1.04 | -- | -- | 1,674,923.00 | 14.17 | -41.75 | 42.53 | -55.57 | -- | -- | 13.64 | -302.07 | -- | -- | 0.00 | -- | 6,068.12 | 24.29 | 95.97 | -- | -59.57 | -- |
Sentient Brands Holdings Inc | 0.00 | -818.63k | 3.86m | 2.00 | -- | -- | -- | -- | -0.0145 | -0.0145 | 0.00 | -0.036 | 0.00 | 0.0188 | -- | 0.00 | -317.87 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0354 | -2.27 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
Cyclacel Pharmaceuticals Inc | 449.00k | -19.85m | 3.86m | 12.00 | -- | -- | -- | 8.60 | -21.99 | -21.99 | 0.4636 | -1.67 | 0.0318 | -- | 0.1204 | -- | -139.57 | -57.58 | -314.22 | -69.81 | -- | -- | -4,386.86 | -18,789.29 | -- | -128.51 | -- | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 3.96m | 24.00 | -- | -- | -- | 0.2784 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
Phio Pharmaceuticals Corp | 0.00 | -9.38m | 3.98m | 8.00 | -- | 0.5981 | -- | -- | -3.71 | -3.71 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -113.26 | -71.92 | -145.23 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
Alzamend Neuro Inc | 0.00 | -12.40m | 4.06m | 4.00 | -- | -- | -- | -- | -1.87 | -1.87 | 0.00 | -0.572 | 0.00 | -- | -- | 0.00 | -267.15 | -- | -880.90 | -- | -- | -- | -- | -- | -- | -1,352.90 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
Evoke Pharma Inc | 6.11m | -7.13m | 4.08m | 4.00 | -- | 1.17 | -- | 0.6688 | -1.83 | -1.83 | 1.28 | 0.4068 | 0.5429 | 0.5113 | 5.71 | 1,526,428.00 | -63.39 | -100.48 | -76.67 | -151.10 | 96.01 | -- | -116.76 | -480.52 | 5.35 | -19.25 | 0.5884 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
Regen BioPharma Inc | 236.58k | -851.69k | 4.11m | 1.00 | -- | -- | -- | 17.39 | -0.2271 | -0.2271 | 0.0633 | -1.26 | 0.8644 | -- | 3.98 | 236,580.00 | -327.54 | -104.36 | -- | -- | -- | -- | -378.93 | -275.00 | -- | -1.32 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
Kiromic Biopharma Inc | 0.00 | -24.99m | 4.12m | 31.00 | -- | -- | -- | -- | -29.21 | -29.21 | 0.00 | -3.81 | 0.00 | -- | -- | 0.00 | -171.18 | -161.49 | -- | -213.01 | -- | -- | -- | -- | -- | -15.69 | 1.87 | -- | -- | -- | -35.90 | -- | 177.42 | -- |
Zyversa Therapeutics Inc | 0.00 | -105.53m | 4.12m | 7.00 | -- | 0.3675 | -- | -- | -1,791.54 | -1,791.54 | 0.00 | 13.44 | 0.00 | -- | -- | 0.00 | -142.87 | -- | -164.77 | -- | -- | -- | -- | -- | -- | -17,576.86 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
Neximmune Inc | 0.00 | -25.86m | 4.20m | 6.00 | -- | 1.53 | -- | -- | -24.16 | -24.16 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -130.41 | -115.07 | -183.16 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
Holder | Shares | % Held |
---|---|---|
Renaissance Technologies LLCas of 31 Mar 2024 | 20.84k | 1.58% |
Point72 Asset Management LPas of 31 Mar 2024 | 15.33k | 1.16% |
Acadian Asset Management LLCas of 31 Mar 2024 | 14.29k | 1.08% |
UBS Securities LLCas of 31 Mar 2024 | 4.84k | 0.37% |
Tower Research Capital LLCas of 31 Mar 2024 | 4.19k | 0.32% |
McIlrath & Eck LLCas of 31 Mar 2024 | 832.00 | 0.06% |
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 126.00 | 0.01% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 80.00 | 0.01% |
Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 33.00 | 0.00% |
SignatureFD LLCas of 31 Mar 2024 | 20.00 | 0.00% |